Skip to main content
. Author manuscript; available in PMC: 2022 Mar 1.
Published in final edited form as: Brain Behav Immun. 2021 Jan 7;93:80–95. doi: 10.1016/j.bbi.2020.12.016

Figure 5. Systemic administration of the TLR4 antagonist XT-203 beginning 15 days after intradermal myelin oligodendrocyte glycoprotein (MOG), reverses EAE-related pain in male Dark Agouti rats.

Figure 5.

Male Dark Agouti rats were baselined (BL) for motor scores and for low-threshold mechanical withdrawal thresholds via the von Frey test, followed by intra-dermal low-dose (4 µg) myelin oligodendrocyte glycoprotein (MOG). Allodynia and motor scores were assessed thereafter across the timecourse shown. XT-203 (15 mg/kg subcutaneously [SC] 3x/day) vs. saline was initiated on Day 15 post-MOG, continuing through day 30 (see gray rectangle indicating span of drug delivery). Panels A and B: XT-203 reversed allodynia, relative to saline control. Main effect of drug: left paw: F(1,8) =11.39, p<0.01; right paw: F(1,8) =75.8, p<0.0001. Panel C: (+)-NTX did not reliably increase motor scores. N=5/group.